[go: up one dir, main page]

PE20170957A1 - Agonistas parciales del receptor de insulina - Google Patents

Agonistas parciales del receptor de insulina

Info

Publication number
PE20170957A1
PE20170957A1 PE2017000888A PE2017000888A PE20170957A1 PE 20170957 A1 PE20170957 A1 PE 20170957A1 PE 2017000888 A PE2017000888 A PE 2017000888A PE 2017000888 A PE2017000888 A PE 2017000888A PE 20170957 A1 PE20170957 A1 PE 20170957A1
Authority
PE
Peru
Prior art keywords
chain
insulin
polypeptide
heterodimer
partial
Prior art date
Application number
PE2017000888A
Other languages
English (en)
Inventor
Songnian Lin
Lin Yan
Pei Huo
Dmitri Pissarnitski
Danqing Feng
Ravi Nargund
Yuping Zhu
Ahmet Kekec
Christina B Madsen-Duggan
Zhi-Cai Shi
Zhicai Wu
Yingjun Mu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20170957A1 publication Critical patent/PE20170957A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un agonista parcial del receptor de insulina que comprende un primer heterodimero de insulina o analogo de insulina y un segundo heterodimero o analogo de insulina incluyendo cada heterodimero un polipeptido de cadena A y un polipeptido de cadena B, en el que el polipeptido de cadena A y el polipeptido de cadena B estan unidos a traves de enlaces disulfuro intercatenarios; en el que el primero y segundo heterodimero de insulina o analogo de insulina estan unidos covalentemente juntos a traves de un resto de union que conecta la cadena lateral de un aminoacido en o cerca del extremo carboxi terminal de los dos polipeptidos respectivos de cadena B y en el que el extremo amino terminal de al menos uno de los polipeptidos de cadena A y los de cadena B esta unido covalentemente a un sustituyente, con la condicion de que el resto de union no incluya un enlace disulfuro. Tambien se refiere a una composicion farmaceutica. Dicho agonista parcial es util en el tratamiento de la diabetes de tipo I, tipo II y diabetes gestacional.
PE2017000888A 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina PE20170957A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
PE20170957A1 true PE20170957A1 (es) 2017-07-13

Family

ID=54838417

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000888A PE20170957A1 (es) 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina

Country Status (26)

Country Link
US (4) US20170355743A1 (es)
EP (4) EP3660041B1 (es)
JP (5) JP6484337B2 (es)
KR (2) KR102101136B1 (es)
CN (2) CN108064173B (es)
AR (1) AR102712A1 (es)
AU (3) AU2015349890B2 (es)
CA (2) CA3014641C (es)
CL (3) CL2017001288A1 (es)
CO (1) CO2017004976A2 (es)
CR (1) CR20170208A (es)
DO (1) DOP2017000124A (es)
EA (1) EA036714B1 (es)
ES (2) ES2946247T3 (es)
GT (1) GT201700104A (es)
IL (1) IL252257A0 (es)
MX (3) MX2017006651A (es)
NI (1) NI201700060A (es)
PE (1) PE20170957A1 (es)
PH (1) PH12017500935A1 (es)
SG (4) SG10201809457YA (es)
SV (1) SV2017005445A (es)
TN (1) TN2017000178A1 (es)
TW (1) TW201625673A (es)
WO (1) WO2016081670A2 (es)
ZA (1) ZA201703238B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2957046C (en) 2014-08-04 2022-11-15 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EP3660041B1 (en) * 2014-11-21 2023-04-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
US10953076B2 (en) 2016-05-24 2021-03-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and GLP-1 analogues
EP3463413A4 (en) * 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. INSULIN RECEPTOR PART AGONISTS
EP3529615A1 (en) * 2016-10-24 2019-08-28 Novo Nordisk A/S Bioassay for insulin formulations
JP2020531451A (ja) 2017-08-17 2020-11-05 ノヴォ ノルディスク アー／エス 新規のアシル化インスリン類似体およびそれらの使用
WO2020028864A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
WO2022046747A1 (en) * 2020-08-26 2022-03-03 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
US20230310551A1 (en) * 2020-08-26 2023-10-05 Merck Sharp & Dohme Llc Insulin receptor partial agonists
CN116457015A (zh) * 2020-09-03 2023-07-18 达因疗法公司 制备蛋白质-寡核苷酸复合物的方法
WO2022051665A1 (en) * 2020-09-03 2022-03-10 Dyne Therapeutics, Inc. Methods of preparing protein-oligonucleotide complexes
US20240294596A1 (en) * 2020-09-09 2024-09-05 Merck Sharp & Dohme Llc Insulin receptor partial agonists
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
WO1996034882A1 (en) 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
WO1999064045A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
KR101048279B1 (ko) 2002-05-30 2011-07-13 더 스크립스 리서치 인스티튜트 구리 촉매 작용하에서의 아지드와 아세틸렌과의 리게이션
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
CN1902226A (zh) 2003-12-03 2007-01-24 诺和诺德公司 单链胰岛素
EP1807105A2 (en) 2004-10-27 2007-07-18 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
WO2006050262A2 (en) 2004-11-01 2006-05-11 The Regents Of The University Of California Compositions and methods for modification of biomolecules
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
KR20110021758A (ko) 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CN103736082A (zh) * 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
EP2627670A2 (en) * 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
EP2771026A4 (en) * 2011-10-27 2015-08-05 Univ Case Western Reserve ULTRA-CONCENTRATED AND FAST-ACTING INSULIN ANALOG FORMULATIONS
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
CA2904198A1 (en) 2013-03-15 2014-09-18 Universite De Geneve Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
WO2015051052A2 (en) * 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3068443B1 (en) * 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Residualizing linkers and uses thereof
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
EP3660041B1 (en) * 2014-11-21 2023-04-19 Merck Sharp & Dohme LLC Insulin receptor partial agonists

Also Published As

Publication number Publication date
KR102101136B1 (ko) 2020-04-14
IL252257A0 (en) 2017-07-31
EP3660041A1 (en) 2020-06-03
CA2966765A1 (en) 2016-05-26
AU2018211207A1 (en) 2018-08-16
US20170355743A1 (en) 2017-12-14
JP2019014735A (ja) 2019-01-31
WO2016081670A2 (en) 2016-05-26
AU2015349890A1 (en) 2017-06-01
KR20190069622A (ko) 2019-06-19
EP3660040B1 (en) 2025-06-18
SG10201809428UA (en) 2018-11-29
JP2020097572A (ja) 2020-06-25
AU2018211208B2 (en) 2020-09-10
EP3666792A3 (en) 2020-07-29
JP6484337B2 (ja) 2019-03-13
JP2019014734A (ja) 2019-01-31
EP3660041B1 (en) 2023-04-19
CN112494656A (zh) 2021-03-16
TN2017000178A1 (en) 2018-10-19
JP6931033B2 (ja) 2021-09-01
CA3014641A1 (en) 2016-05-26
US20180291078A1 (en) 2018-10-11
EA036714B1 (ru) 2020-12-10
JP2018501203A (ja) 2018-01-18
WO2016081670A3 (en) 2016-08-04
ZA201703238B (en) 2018-05-30
KR102049647B1 (ko) 2019-11-29
AU2018211208A1 (en) 2018-08-16
NI201700060A (es) 2017-07-18
SG10201809427SA (en) 2018-11-29
JP6943825B2 (ja) 2021-10-06
EP3221343A2 (en) 2017-09-27
GT201700104A (es) 2018-11-27
EP3666792B1 (en) 2024-12-18
ES3004386T3 (en) 2025-03-12
MX2017006651A (es) 2017-08-21
CN112494656B (zh) 2024-01-30
US10183981B2 (en) 2019-01-22
EP3660040A2 (en) 2020-06-03
ES2946247T3 (es) 2023-07-14
CL2019001144A1 (es) 2019-07-19
CL2017001288A1 (es) 2017-12-15
BR122024000898A2 (pt) 2024-02-27
SG11201704064TA (en) 2017-06-29
EP3660040A3 (en) 2020-07-29
MX2020014120A (es) 2021-03-25
SV2017005445A (es) 2018-04-04
CL2019001143A1 (es) 2019-07-19
BR112017010481A8 (pt) 2023-04-11
DOP2017000124A (es) 2017-08-15
JP2019011357A (ja) 2019-01-24
AU2018211207B2 (en) 2020-04-09
JP6703068B2 (ja) 2020-06-03
CN108064173A (zh) 2018-05-22
CA3014641C (en) 2020-08-18
BR112017010481A2 (pt) 2018-04-03
BR122024000903A2 (pt) 2024-02-27
US20170107268A1 (en) 2017-04-20
KR20170084300A (ko) 2017-07-19
CR20170208A (es) 2017-07-17
US10800827B2 (en) 2020-10-13
PH12017500935A1 (en) 2017-11-27
CO2017004976A2 (es) 2017-10-10
AR102712A1 (es) 2017-03-22
EP3666792A2 (en) 2020-06-17
SG10201809457YA (en) 2018-11-29
US20190092833A1 (en) 2019-03-28
TW201625673A (zh) 2016-07-16
EA201791117A1 (ru) 2017-11-30
AU2015349890B2 (en) 2018-08-30
CA2966765C (en) 2020-04-14
CN108064173B (zh) 2021-05-18
MX2020014121A (es) 2021-03-25
EP3221343B1 (en) 2020-09-16
US10017556B2 (en) 2018-07-10

Similar Documents

Publication Publication Date Title
PE20170957A1 (es) Agonistas parciales del receptor de insulina
PE20171058A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
PE20121636A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
SV2017005548A (es) Proteinas de fusion
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
PE20170896A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
CY1123615T1 (el) Πολυσθενεις και πολυειδικες συντηγμενες πρωτεïνες που δεσμευουν τον dr5
AR099079A1 (es) Variantes de región fc con propiedades de unión de fcrn modificadas
AR100888A1 (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
ES2572388T3 (es) Heterodímeros del MHC de clase II solubles funcionales estabilizados por enlaces disulfuro
CL2015000060A1 (es) Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia.
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
EA202091342A2 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
MX2018006181A (es) Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
MX2016011580A (es) Dominios de fibronectina tipo iii que se unen a albumina de suero.
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
UY35018A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico.
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
CL2015002720A1 (es) Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
MX2018001803A (es) Metodo para disgnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
WO2016105545A3 (en) Insulin analogues with enhanced stabilized and reduced mitogenicity
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MY178931A (en) Polypeptides with permease activity